Transforming the Non-injectable Insulin Market in 2025: Expanding Non-Injectable Insulin Market Fueled by Escalating Obesity and Diabetes Epidemics

What Is the Expected Size and Growth Rate of the Non-injectable Insulin Market?
The non-injectable insulin market has expanded rapidly in recent years. It is expected to rise from $1.92 billion in 2024 to $2.16 billion in 2025, with a CAGR of 12.1%. Factors contributing to past growth include improved patient compliance, solutions addressing needle phobia, enhancements in quality of life, ease of administration, and more effective blood glucose control.

The non-injectable insulin market is expected to grow rapidly, reaching $3.17 billion by 2029 at a CAGR of 10.1%. This growth is due to continued emphasis on patient compliance, solutions for needle phobia, improvements in quality of life, enhanced safety, and reduced infection risks. Key trends include technological advancements, digital health integration, nanotechnology applications, and combination therapies.

What Factors Are Fueling Growth in the Non-injectable Insulin Market?
The increasing prevalence of obesity and diabetes is anticipated to drive the expansion of the non-injectable insulin market in the coming years. Obesity is a condition marked by excessive fat accumulation due to an imbalance between calorie intake and energy expenditure, whereas diabetes mellitus is a group of metabolic disorders leading to persistently high blood sugar levels. Non-injectable insulin plays a vital role in managing both conditions, helping overcome barriers to insulin therapy, supporting weight management, and providing more convenient treatment alternatives. For example, in 2022, the World Heart Federation, a Switzerland-based non-governmental organization, reported that global obesity rates were on the rise, with 2.3 billion individuals-including both children and adults-experiencing overweight and obesity in 2021, a number projected to reach 2.7 billion by 2025. Additionally, in April 2023, the British Diabetic Association, a UK-based diabetes charity, stated that 4.3 million people in the UK were diagnosed with diabetes, while over 2.4 million were at high risk of developing type 2 diabetes. The 2021-22 registration data showed an increase of 148,951 cases compared to the previous year. Thus, the rising incidence of obesity and diabetes is fueling the growth of the non-injectable insulin market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which Leading Companies Are Shaping the Growth of the Non-injectable Insulin Market?
Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What Are the Major Trends Shaping the Non-injectable Insulin Market?
Leading companies in the non-injectable insulin market are prioritizing advancements in drug delivery systems, such as needle-free oral insulin sprays, to enhance the quality of life for individuals requiring multiple insulin injections. These sprays provide a painless and needle-free approach to blood glucose regulation, offering a convenient option as the insulin can be directly sprayed into the mouth. For example, in November 2023, NiedlFree Technologies, an India-based technology firm, introduced Ozulin, an oral insulin spray. This innovation aims to offer a more user-friendly insulin delivery method, particularly benefiting individuals who struggle with traditional injection-based insulin therapies. If approved, Ozulin could revolutionize diabetes management by providing a more accessible and pain-free alternative.

What Are the Key Segments of the Non-injectable Insulin Market?
The non-injectable insulin market covered in this report is segmented -

1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:
1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin
2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Dominates the Non-injectable Insulin Market?
North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Non-injectable Insulin Global Market Report?

- Market Size Analysis: Analyze the Non-injectable Insulin Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Non-injectable Insulin Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Non-injectable Insulin Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Non-injectable Insulin Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.